EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Deprescribing in older patients with hyperpolypharmacy: a cluster-randomised trial in primary care

Gert Baas iD, Mette Heringa, Sanne Verdoorn, Henk-Frans Kwint, Eman Badawy, Jacobijn Gussekloo iD, Jako Burgers, Petra Denig, Marcel L Bouvy iD

Age and Ageing · 02.07.2026 · 55 (7)

DOI: 10.1093/ageing/afag209 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Age and Ageing, online erschienen am 19.07.2026. Verfasst von Gert Baas und 8 weiteren Autor:innen. Beteiligte Einrichtung: SIR Institute for Pharmacy Practice and Policy, Leiden, ZH, The Netherlands. Hauptthemen laut MEDLINE: Polypharmacy, Deprescriptions, Primary Health Care, Pharmacists. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Polypharmacy increases the risk of adverse drug events and potentially preventable hospital admissions. Deprescribing may reduce medication-related harm, and a clinical medication review (CMR) provides an opportunity to support this.

Objective

To investigate the effect of a deprescribing-focused CMR by trained pharmacists on the number of reduced and stopped medications among patients aged ≥75 years with hyperpolypharmacy using multidose-drug-dispensing (MDD)-systems.

Methods

In this cluster-randomised controlled trial, pharmacists were trained to perform a deprescribing-focused CMR, while control pharmacies provided usual care. Eligible patients were aged ≥75 years, had hyperpolypharmacy and used MDD. Dispensing data were used to determine the number of reduced and stopped medications per patient after 6 months (primary outcome). Secondary outcomes were: total number of medications, health problems and quality-of-life (EQ-5D-5L, EQ-VAS). A generalised linear mixed model was used for the primary outcome.

Results

A total of 318 patients from 58 pharmacies were enrolled (155 intervention, 163 control). At 6 months, patients in the intervention group had significantly more medications deprescribed than those in the control group (mean 2.5 vs. 1.7 per patient; mean difference 0.79, 95% CI 0.29–1.28; P = .002). There was no significant between-group difference in the total number of medications at 6 months (intervention −0.30 vs. control +0.12; P = .108). No significant differences were observed in health problems or quality-of-life.

Conclusion

Deprescribing-focused CMRs by trained pharmacists successfully increased reduction and stopping of medications in older patients with hyperpolypharmacy using MDD-systems, while no changes in health problems or health-related quality of life could be observed over 6 months.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PolypharmacyDeprescriptionsPrimary Health CarePharmacistsDrug-Related Side Effects and Adverse ReactionsMedication ReviewHumansAgedFemaleMaleAged, 80 and overQuality of LifeAge FactorsTime FactorsInappropriate Prescribing

Stichwörter der Autor:innen

(hyper)polypharmacydeprescribingmedication reviewolder peoplerandomised controlled trial

Autor:innen und Institutionen

  • SIR Institute for Pharmacy Practice and Policy, Leiden, ZH, The Netherlands.
  • Department of Pharmaceutical Sciences, Utrecht University, Utrecht 125, The Netherlands.
  • Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Family Medicine, Maastricht University, Maastricht, LI, The Netherlands.
  • Dutch College of General Practitioners (NHG), Utrecht, The Netherlands.
  • Clinical Pharmacy & Pharmacology, University of Groningen, University Medical Center Groningen, PO Box 30001 EB71, Groningen 9700RB, The Netherlands.

ORCID-Profile: Gert Baas, Jacobijn Gussekloo, Marcel L Bouvy

Zitieren

APA

Baas, G., Heringa, M., Verdoorn, S., Kwint, H. F., Badawy, E., Gussekloo, J., Burgers, J., Denig, P., & Bouvy, M. L. (2026). Deprescribing in older patients with hyperpolypharmacy: a cluster-randomised trial in primary care. Age and Ageing, 55(7). https://doi.org/10.1093/ageing/afag209

Vancouver

Baas G, Heringa M, Verdoorn S, Kwint HF, Badawy E, Gussekloo J, et al. Deprescribing in older patients with hyperpolypharmacy: a cluster-randomised trial in primary care. Age and Ageing. 2026;55(7). doi:10.1093/ageing/afag209

BibTeX
@article{Baas2026,
  author = {Baas, Gert and Heringa, Mette and Verdoorn, Sanne and Kwint, Henk-Frans and Badawy, Eman and Gussekloo, Jacobijn and Burgers, Jako and Denig, Petra and Bouvy, Marcel L},
  title = {Deprescribing in older patients with hyperpolypharmacy: a cluster-randomised trial in primary care},
  journal = {Age and Ageing},
  year = {2026},
  volume = {55},
  number = {7},
  doi = {10.1093/ageing/afag209}
}
Kostenlos starten →